Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / PHARMACEUTCL ETF
-
Number of holders
-
123
-
Total 13F shares, excl. options
-
7.88M
-
Shares change
-
-57.3K
-
Total reported value, excl. options
-
$712M
-
Value change
-
-$3.74M
-
Put/Call ratio
-
11.2
-
Number of buys
-
56
-
Number of sells
-
-61
-
Price
-
$90.36
Significant Holders of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) as of Q3 2025
153 filings reported holding PPH - VANECK ETF TRUST - PHARMACEUTCL ETF as of Q3 2025.
VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) has 123 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.88M shares
.
Largest 10 shareholders include GOLDMAN SACHS GROUP INC (1.9M shares), HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND (1.03M shares), CITIGROUP INC (718K shares), MORGAN STANLEY (656K shares), WELLS FARGO & COMPANY/MN (500K shares), Clal Insurance Enterprises Holdings Ltd (325K shares), J.Safra Asset Management Corp (286K shares), Avalon Trust Co (275K shares), JPMORGAN CHASE & CO (257K shares), and Miller Investment Management, LP (182K shares).
This table shows the top 123 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.